Baseline data from the ongoing CARDIO-TTRansform trial of eplontersen vs placebo in 1432 patients with transthyretin amyloid cardiomyopathy: mean age 76.4, 9.4% female, 14.7% hereditary, median NT-proBNP 2025 pg/ml, 57.2% on a TTR stabiliser. No outcome results yet.
RCTn = 1,432
Fontana et al. Baseline characteristics of patients with transthyretin amyloid cardiomyopathy in the CARDIO-TTRansform trial of eplontersen